LAG3 and colonic neoplasm: First, efficacy for ZGGS15 (only the anti-LAG-3 part is active in this model) plus anti-PD-1 in the BALB/c-hPD-1/hLAG-3 mouse bearing CT26 colon cancer model was performed.